The nightmare on the public markets is not confined to the bigger groups.
Forthcoming data in colorectal cancer screening could put the company’s liquid biopsy on the market – but it looks like Guardant might get there first.
The sequencing sector is changing fast, but Pacbio believes its technology can hold out against its rivals.
Insulin pumps and glucose sensors flew off the shelves, whereas liquid biopsy developers both soared and sank.
Emergence from lockdown is the driving force behind many – but not all – of the small and mid-cap share price moves.
Cancer diagnosis is likely to see a huge resurgence in demand as the pandemic ebbs, and Invitae wants to be ready.